The Effect of Granulocyte Macrophage-Colony Stimulating Factor upon the Induction of Peripheral Blood Dendritic and Natural Killer Cells When Given Simultaneously with a Slow Continuous Doxorubicin Infusion — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
The Effect of Granulocyte Macrophage-Colony Stimulating Factor upon the Induction of Peripheral Blood Dendritic and Natural Killer Cells When Given Simultaneously with a Slow Continuous Doxorubicin Infusion
Division of Medical Oncology, Thomas Jefferson School of Medicine, Philadelphia, USA
,
Division of Medical Oncology, Thomas Jefferson School of Medicine, Philadelphia, USA
,
Division of Surgery, North Penn Hospital, Landsdale, USA
1 Division of Medical Oncology, Thomas Jefferson School of Medicine, Philadelphia, USA
2 Division of Medical Oncology, Thomas Jefferson School of Medicine, Philadelphia, USA
3 Division of Surgery, North Penn Hospital, Landsdale, USA
It has been demonstrated that it is safe to give Gm-Csf, together with Doxorubicin, by continuous intravenous infusion, thereby substantially increasing the amount of Doxorubicin administered to the average patient, and assuring that each patient receives an individually-determined safe and maximal amount of drug. It is known that Gm-Csf is a potent inducer of components that are major factors in an immunologic attack upon neoplasms. For that reason, we thought it would be worth evaluating in 4 patients’ surface markers of dendritic precursor cells, dendritic cells [DC], and natural killer [NK] cells during the infusion. While there was substantial variation in individual responses, all 4 patients receiving Gm-Csf developed persistent marked increases in cells with each of these markers. The significance of these findings will be discussed.
Weiss, A.J. and Stoloff, I.L. (2015) Three Protocols Designed to Individualize and Maximize Anti-Cancer Drug Therapy. Journal of Cancer Therapy, 6, 1103-1113. https://doi.org/10.4236/jct.2015.612120
Weiss, A.J. and Lackman R.D. (1997) Infusional Chemotherapy Combined with Hematopoetic Growth Factors Advantages and Limitations. American Journal of Clinical Oncology, 20, 63-66. https://doi.org/10.1097/00000421-199702000-00014
MacDonald, K.P., Munster, D.J., Clark, G.J., Dzionek, A., Schmitz, J. and Hart, D.N. (2002) Characterization of Human Blood Dendritic Cell Subsets. Blood, 100, 4512-4520. https://doi.org/10.1182/blood-2001-11-0097
Palucka, K. and Banchereau, J. (2012) Cancer Immunotherapy via Dendritic Cells. Nature Reviews Cancer, 12, 265-277. https://doi.org/10.1038/nrc3258
Nizzoli, G., Krietsch, J., Weick, A., Steinfelder, S., Facciotti, F., Gruarin, P., Bianco, A., Steckel, B., Moro, M., Crosti, M., et al. (2013) Human CD1c+ Dendritic Cells Secrete High Levels of IL-12 and Potently Prime Cytotoxic T-Cell Responses. Blood, 122, 932-942. https://doi.org/10.1182/blood-2013-04-495424
Breton, G., Lee, J., Zhou, Y.J., Schreiber, J.J., Keler, T., Puhr, S., Anandasabapathy, N., Schlesinger, S., Caskey, M., Liu, K. and Nussenzweig, M.C. (2015) Circulating Precursors of Human CD1c+ and CD141+ Dendritic Cells. Journal of Emergency Medicine, 212, 401. https://doi.org/10.1084/jem.20141441
Morse, E., Anderson, P. and Caligiuri, M.A. (1996) Caligiuri Role of Interleukin-15 in the Development of Human CD56+ Natural Killer Cells from CD34+ Hematopoietic Progenitor Cells. Blood, 87, 2632-2640.
Miller, J.S., McCullar, V., Punzel, M., Lemischka, I.R. and Moore, K.A. (1999) Single Adult Human CD34(+)/Lin-/CD38(-) Progenitors Give Rise to Natural Killer Cells, B-Lineage Cells, Dendritic Cells, and Myeloid Cells. Blood, 93, 96-106.
Frey, M., Packianathan, N.B., Fehniger, T.A., Ross, M.E., Wang, W.C., Stewart, C.C., Caligiuri, M.A. and Evans, S.S. (1998) Differential Expression and Function of L-Selectin on CD56bright and CD56dim Natural Killer Cell Subsets. The Journal of Immunology, 161, 400-408.
Cooper, M.A., Fehniger, T.A., Turner, S.C., Chen, K.S., Ghaheri, B.A., Ghayur, T., Carson, W.E. and Caligiuri, M.A. (2001) Human Natural Killer Cells: A Unique Innate Immunoregulatory Role for the CD56 (Bright) Subset. Blood, 97, 3146-3151. https://doi.org/10.1182/blood.V97.10.3146
Colucci, F., Caligiuri, M.A. and Di Santo, J.P. (2003) What Does It Take to Make a Natural Killer? Nature Reviews Immunology, 3, 413-425. https://doi.org/10.1038/nri1088
Meropol, N.J., Miller, L.L., Korn E.L., Braitman, L.E., MacDermott M.L. and Schuchter, L.M. (1992) Severed Myelosuppression Resulting from Concurrent Administration of Granulocyte Colony-Stimulating Factor and Cytotoxic Chemotherapy. Journal of the National Cancer Institute, 84, 1201-1203. https://doi.org/10.1093/jnci/84.15.1201
Rowinsky, E.K., et al. (1992) Phase I and Pharmacologic Study of Topotecan, an Inhibitor of Topoisomerase I with Granulocyte Colony-Stimulating (G-CSF) Toxicologic Differences between Concurrent and Post Treatment G-CSF Administration. Journal of Clinical Oncology, 11, 284.
Lokich, J. (1999) Single-Dose Granulocyte Colony-Stimulating Factor Concomitant with Multifractionated Dose Chemotherapy. A Strategy for Maintaining Dose Intensity Cancer Investigation, 17, 547-550. https://doi.org/10.3109/07357909909032865
Müller, H.I., Nakchbandi, W., Chatzissavvidis, I. and Valek, V. (2001) Intra-Arterial Infusion of 5-Fluorouracil plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Chemoembolization with Melphalan in the Treatment of Disseminated Colorectal Liver Metastases. European Journal of Surgical Oncology, 27, 652-661. https://doi.org/10.1053/ejso.2001.1193
Ottman, O.G., Hoelzer, D., Gracien, E., Ganser, A., Kelly, K., et al. (1995) Concomitant Granulocyte Colony-Stimulating Factor and Induction Chemoradiotherapyin Adult Acute Lymphoblastic Leukemia A randomized Phase Three Trial. Blood, 444-450.
Tessoulin, B., Thomare, P., Delande, E., Moynard, J., Gastinne, T., Moreau, A., Bossard, C., Mahé, B., Blin, N., Dubruille, V., Touzeau, C., Boudreault, J.S., Perrin, F., Lok, A., Guillaume, T., Garnier, A., Peterlin, P., Gallas, P., Chevallier, P. and Moreau, P. (2017) Carboplatin Instead of Cisplatin in Combination with Dexamethasone, High-Dose Cytarabine with or without Rituximab (DHAC+/-R) Is An Effective Treatment with Low Toxicity in Hodgkin’s and Non-Hodgkin’s Lymphoma. Annals of Hematology, 96, 943-950. https://doi.org/10.1007/s00277-017-2981-2
Weiss, A.J., Metter, G.E., Fletcher, W.S., Wilson, W.L., Grage, T.B. and Ramirez, G. (1976) Studies of Adriamycin Using a Weekly Regime Demonstrating Its Clinical Effectiveness and Lack of Cardiac Toxicity. Cancer Treatment Reports, 60, 813-822.
Starling, K.A., Berry, D.H., Britton, H.A., Humphrey, G.B., Vats, T. and Ragab, A.H. (1975) Three Dose Regimens of Adriamycin for Induction of Remission in Acute Leukemia in Children: A Southwest Oncology Group Study. Medical and Pediatric Oncology, 1, 271-276. https://doi.org/10.1002/mpo.2950010309
Berrak, S.G., Ewer, M.S., Jaffe, N., Pearson, P., Ried, H., Zietz, H.A. and Benjamin, R.S. (2001) Doxorubicin Cardiotoxicity in Children: Reduced Incidence of Cardiac Dysfunction Associated with Continuous-Infusion Schedules. Oncology Reports, 8, 611-614. https://doi.org/10.3892/or.8.3.611
Torti, F.M., Bristow, M.R., Howes, A.E., Aston, D., Stockdale, F.E., Carter, S.K., Kohler, M., Brown, B.W.J. and Billingham, M.E. (1983) Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule. Assessment by Endomyocardial Biopsy. Annals of Internal Medicine, 99, 745-749. https://doi.org/10.7326/0003-4819-99-6-745
Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., et al. (2010) Granulocyte-Colony Stimulating Factor Promotes Lung Metastasis through Mobilization of Ly6G+Ly6C+ Granulocytes. Proceedings of the National Academy of Sciences of the United States of America, 107, 21248-21255. https://doi.org/10.1073/pnas.1015855107
Wang, J., Yao, L., Zhao, S., Zhang, X., Yin, J., Zhang, Y., et al. (2012) Granulocyte-Colony Stimulating Factor Promotes Proliferation, Migration and Invasion in Glioma Cells. Cancer Biology & Therapy, 13, 389-400. https://doi.org/10.4161/cbt.19237
Francis, S., Cheng, S., Arteaga, C. and Moslehi, J. (2004) Heart Failure and Breast Cancer Therapies: Moving towards Personalized Risk Assessment. Journal of the American Heart Association, 3, Article ID: e000780.
Force, T., Krause, D.S. and Van, E.R.A. (2007) Molecular Mechanisms of Cardiotoxicity of Tyrosine Kinase Inhibition. Nature Reviews Cancer, 7, 332-344. https://doi.org/10.1038/nrc2106
Wing, E.J., Magee, D.M., Whiteside, T.L., Kaplan, S.S. and Shadduck, R.K. (1989) Recombinent Human Granulocyte/Macrophage Colony-Stimulating Factor Enhances Monocyte Cytotoxicity and Secretion of Tumor Necrosis Factor Alpha and Interferon in Cancer Patients. Blood, 73, 643-646.
Edmonson, J.H., Long, H.J., Kvols, L.K., Mann, B.S. and Grill, J.P. (1998) Can Molgramostim Enhance the Antitumor Effects of Cytotoxic Drugs in Patients with Advanced Sarcomas? Annals of Oncology, 8, 637-641. https://doi.org/10.1023/A:1008292010062
Phillips, N., Jacobs, S., Stoller, R., Earle, M., Przepiorka, D. and Shadduck, R.K. (1989) Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Myelopoiesis in Patients with Refractory Metastatic Carcinoma. Blood, 74, 26-34.
Miguel, A., Herrero, M.J., Sendra, L., Botella, R., Algás, R., Sánchez, M. and Alino, S.F. (2013) Comparative Antitumor Effect among GM-CSF, IL-12 and GM-CSF+IL-12 Genetically Modified Tumor Cell Vaccines. Cancer Gene Therapy, 20, 576-578. https://doi.org/10.1038/cgt.2013.54
Sivori, S., Cantoni, C., Pasolini, E., Marcenaro, R., Conte, L. and Moretta, A. (2003) IL-21 Induces Both Rapid Maturation of Human CD34+ Cell Precursors towards NK Cells and Acquisition of Surface Killer Ig-Like Receptors. European Journal of Immunology, 33, 3439-3447. https://doi.org/10.1002/eji.200324533
Hiasa, M., Abe, M., Nakano, A., Oda, A., Amou, H., Kido, S., Takeuchi, K., Kagawa, K., Yata, K., Hashimoto, T., Ozaki, S., Asaoka, K., Tanaka, E., Moriyama, K. and Matsumoto, T. (2009) GM-CSF and IL-4 Induce Dendritic Cell Differentiation and Disrupt Osteoclastogenesis through M-CSF Receptorshedding by Up-Regulation of TNF-Alpha Converting Enzyme (TACE). Blood, 114, 4517-4526. https://doi.org/10.1182/blood-2009-04-215020